A retrospective analysis of 1,230 patients transplanted for acute myeloid leukemia in first complete remission (CR1), patients conditioned with IV-Bu and cyclophosphamide had significantly better leukemia-free survival than patients who received cyclophosphamide and TBI (RR=0.70; 95% CI: 0.55-0.88; p=0.003).
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
IV Busulfan Better Than TBI in HCT for AML in CR1
Oct 2013